SecBot SecBot
SECBOTREPLAY Home › Report › ASND

ASND · Ascendis Pharma announced positive Week 52 results from its Phase 2 New…

Ascendis Pharma · PRESS-RELEASE filed Mar 17, 2026 at 08:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Mar 17, 2026 at 08:30 ET

Ascendis Pharma announced positive Week 52 results from its Phase 2 New InsiGHTS trial, showing that once-weekly TransCon hGH achieved annualized height velocity (9.05 cm/year) comparable to daily somatropin (9.04 cm/year) in children with Turner syndrome, with a similar safety profile and no cases of slipped capital femoral epiphysis. The data support ongoing Phase 3 HighLiGHts trial efforts for potential label expansion into growth hormone sufficiency indications.

  • TransCon hGH demonstrated annualized height velocity of 9.05 cm/year (LS mean) at Week 52, vs. 9.04 cm/year for daily somatropin
  • Trial included 49 prepubertal children with Turner syndrome aged 1–10 years
  • No occurrences of slipped capital femoral epiphysis (SCFE) in TransCon hGH group
  • Adverse events were mild to moderate; none led to discontinuation

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access